Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate

  title={Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate},
  author={Ulrich K. Wenderoth and G{\"u}nther H. Jacobi},
  journal={World Journal of Urology},
SummarySince the introduction of contrasexual treatment as the basic concept of palliation of prostatic carcinoma in the 1940's, orchiectomy, estrogens, and, in recent years, antiandrogens have become generally accepted treatment forms. Three facts: 1) estrogen treatment being at best palliative and at worst dangerous; 2) surgical castration having psychological impacts, at least in the younger age group; and 3) both being probably ineffective from the beginning, have led us to investigate an… 
9 Citations

Buserelin in the treatment of prostatic cancer.

  • F. Roila
  • Medicine, Biology
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  • 1989

Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.

The elevation in serum PAP at the beginning of the agonist treatment and the small residual testicular T production after 6 months may not be clinically important, however, they indicate the necessity of comparative long term studies between orchiectomy and GnRH agonists in the treatment of patients with prostatic cancer.

Surgical versus Medical Castration in the Management of Advanced Prostate Cancer

It is observed that, following orchidectomy, patients with advanced prostatic cancer experience relief of pain associated with calcification of lytic bone metastases and a fall in pre-treatment elevated acid phosphatase levels, and the administration of exogenous testosterone caused a return of symptoms.

Is disease flare a problem?

No distinctions have been made between clinical flare, with its manifestations of subjective or objective aggravation of cancer related symptoms, and the biochemical flare that results of the LHRH analog administration and that occurs in a majority of patients and is characterized by increases in testosterone, prostatic acid phosphatase, and prostate specific antigen.

Treatment of prostatic cancer. Newer forms of androgen deprivation.

Encouraging the initiation of androgen deprivation for patients with regional or distant metastases will improve the patient's course and attempts to provide a more complete androgen blockade hold the hope of delaying or preventing relapse, which usually occurs with continued androgens deprivation.

Die Therapie des fortgeschrittenen Prostatakarzinoms mit Buserelin-Implantat

Erstmals sollte nun ein neu entwickeltes Depot-Praparat1 nach subcutaner Implantation auf Gleichmasigkeit der Buserelin-Abgabe und Kontinuitat der Testosteronsuppression bei Patienten mit fortgeschrittenem Prostatakarzinom (PCA) uberpruft werden.

La Terapia Ormonale Nel Cancro Della Prostata: Stato Attuale E Prospettive

II cancro della prostata e la neoplasia urologica pili frequente nell'anziano. Nel nostro paese esso rappresenta la terza causa di morte per neoplasia nel maschio, con circa 4.500 decessi all'anno*.



Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients.

Hoe 766, is a valuable alternative to conventional contrasexual measures for prostate cancer palliation and to improve the patient's compliance, however, the smallest single pernasal dosage effective for maintenance of down-regulation and steroidogenic arrest has still to be determined.

Hormonal Therapy of Prostatic Cancer

Three VACURG studies report that patients with low stage disease who are treated with estrogen have a higher death rate than men not receiving estrogen and in patients with high stage disease, delayed hormonal therapy is as effective as early hormonal therapy.

Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial.

Evaluation after 6 months showed cyproterone acetate to be more effective in the following respects: the significantly different castration effect as judged by plasma testosterone, the objective voiding pattern and tumour response, and side effects and untoward reactions.

Gonadotropin-releasing hormone analogues for prostate cancer: untoward side effects of high-dose regimens acquire a therapeutical dimension.

From the data available today Gn-RH analogues in overstimulatory dosage can be expected to be safe and effective in the palliative treatment of prostate cancer and would thus prove a true alternative to conventional contrasexual measures.

Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man.

Four male transsexual subjects were given a superactive luteinizing hormone-releasing hormone analogue, D-tryptophan-6-LHRH at daily doses of 100 micrograms for 3--6 mo, leading to a normalization of erectile potency and plasma testosterone.

Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive.

We studied the antifertility effects of a potent gonadotropin-releasing hormone agonist, D-Trp6-Pro9-N-ethylamide-LHRH (LHRHA) in eight normal men, who received daily subcutaneous injections for six

Testicular steroid secretion and peripheral serum steroid concentrations in patients with prostatic carcinoma after short-term estrogen treatment.

It is apparent that the effect of estradiol on testicular steroid production is a gradual process which takes several days before it is clearly evident, and was most pronounced in the case of testosterone and 17 alpha-hydroxyprogesterone.

Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases.

For the past eight years the physician has been confronted with problems concerning the selection of the form of endocrine modification most efficacious for the particular needs of the patient, the designation of the most opportune time to institute therapy and the choice of secondary therapy once relapse has occurred.

Luteinizing hormone-releasing hormone does not inhibit testosterone production in rat interstitial cells in vitro.

In vitro testosterone production in response to 1--5 mIU human menopausal gonadotropin was markedly impaired in cells from rats treated with LHRHa for 2 days or longer and in rats treatedwith LHRH longer than 3 days, but the data do not, however, rule out a direct effect of L HRH or LHR Ha on testicular systems other than those involved in steroidogenesis.

Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate

Clinical trials of new therapies of hormone‐resistant prostate cancer take into account the presence of prognostic factors in the analysis of the results of therapeutic programs, to help improve survival from the onset of chemotherapy.